Montara Therapeutics
Montara Therapeutics, Inc.
Montara Therapeutics, Inc. is a preclinical-stage biopharmaceutical company dedicated to the development of innovative therapies for neurological diseases and brain cancers. With a strong emphasis on minimizing peripheral side effects and enhancing the efficacy of treatments, Montara is at the forefront of addressing critical challenges in the neurological therapeutics space.
Products & Team
BrainOnly™ Platform
The BrainOnly™ platform is Montara's core technology designed to facilitate brain-specific drug activity. It enables the development of therapies that selectively target neurological conditions while avoiding the toxicities typically associated with systemic treatments.
The BrainOnly™ platform addresses the significant issue of peripheral side effects, allowing for safer and more effective dosing of central nervous system-targeted therapies, particularly important for patients with severe neurological disorders.
Montara directly addresses the issues of limited treatment effectiveness and substantial side effects associated with current neurological interventions, leading to increased patient discomfort and treatment discontinuation.